MedTrace Logo

Alfuzosin Hydrochloride to Promote Passage of Distal Ureteral Calculi

NCT00177086 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 76

Last updated 2013-03-18

No results posted yet for this study

Summary

This study will assess improvement in the percentage of spontaneous stone passage for distal ureteral calculi for alfuzosin compared to placebo, decrease of pain and narcotic/analgesic use associated with stone passage, decrease of the time to spontaneous stone passage, shift in the size distribution of stones passed towards larger sizes.

Conditions

  • Kidney Calculi
  • Ureteral Calculi
  • Colic

Interventions

OTHER

Alfuzosin Hydrochloride

One tablet every day for 4 weeks

Sponsors & Collaborators

Principal Investigators

  • Manoj Monga, MD · University of Minnesota and VAMC Minneapolis

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-09-30
Primary Completion
2008-01-31
Completion
2008-01-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00177086 on ClinicalTrials.gov